FY2027 1Q IR PRESENTATION September 14, 2026 Results Overview © AIN HOLDINGS INC. All Rights Reserved. 1 Consolidated P/L While the company was affected by factors such as drug price revisions and dispensing fee revisions, net sales increased 33.2%…
FY2027 1Q
IR PRESENTATION
September 14, 2026
Results Overview
© AIN HOLDINGS INC. All Rights Reserved.
1
Consolidated P/L
While the company was affected by factors such as drug price revisions and dispensing fee revisions, net sales
increased 33.2% YoY and 1.4% against the plan due to the contribution of the Sakura Pharmacy Group, which
joined the group. Operating profit increased 8.4% YoY and decreased 17.5% against the plan.
(¥ million)
Net sales
Gross profit
% of net sales
FY2026 1Q
results
132,969
21,854
16.4
FY2027 1Q
plan
174,600
26,610
15.2
FY2027 1Q
results
YoY
change
YoY
change(%)
Vs
plan (%)
177,120
25,872
+44,151
+4,018
+33.2
+18.4
+1.4
(2.8)
14.6
SG&A expenses
17,600
21,020
21,258
+3,658
+20.8
+1.1
Operating profit
4,254
5,590
4,613
+359
+8.4
(17.5)
Ordinary profit
4,259
4,900
3,919
(340)
(8.0)
(20.0)
Profit attributable to
owners of parent
1,930
2,350
1,975
+45
+2.3
(16.0)
1.5
1.3
1.1
Earnings per share(¥)
55.03
66.85
56.18
+1.15
+2.1
(16.0)
EBITDA
8,244
11,760
10,535
+2,291
+27.8
(10.4)
% of net sales
% of net sales
% of net sales
% of net sales
% of net sales
13.2
3.2
3.2
6.2
12.0
3.2
2.8
6.7
12.0
2.6
2.2
5.9
Figures in the table are rounded down
© AIN HOLDINGS INC. All Rights Reserved.
2
Dispensing Pharmacy Business (Consolidated)
Net sales increased 39.3% YoY and 2.4% against the plan due to the contribution of Sakura Pharmacy Group and
the number of prescriptions has remained steady. Operating profit increased 27.2% YoY and decreased 2.3%
against the plan, due to factors such as drug price revisions and dispensing fee revisions.
FY2026 1Q
results
FY2027 1Q
plan
FY2027 1Q
results
Net sales
108,590
147,800
Gross profit
9,139
(¥ million)
% of net sales
SG&A expenses
% of net sales
Operating profit
% of net sales
Segment profit
% of net sales
Number of
pharmacies
YoY
change
YoY
change(%)
151,288
+42,698
+39.3
+2.4
13,000
12,928
+3,789
+41.5
(0.6)
5,052
7,680
7,728
+2,676
+53.0
+0.6
4,087
5,320
5,199
+1,112
+27.2
(2.3)
4,231
5,200
5,128
+897
+21.2
(1.4)
1,302
2,142
2,143
+841
+64.6
+0.0
8.4
4.7
3.8
3.9
8.8
5.2
3.6
3.5
Vs
plan (%)
8.5
5.1
3.4
3.4
Figures in the table are rounded down
Segment profit is adjusted with the ordinary profit of quarterly consolidated statements of income
© AIN HOLDINGS INC. All Rights Reserved.
3
Retail Business (Consolidated)
While the average spending per customer at AINZ & TULPE and Francfranc remained steady, the number of
customers fell short of the plan due to weather-related factors—such as temperatures remained lower than
the previous year—resulting in net sales up 6.7% YoY and decreased 2.9% against the plan, and operating
profit decreased 2.0% YoY and 10.7% against the plan.
(¥ million)
FY2026 1Q
results
FY2027 1Q
plan
FY2027 1Q
results
YoY
change
YoY
change(%)
Vs
plan (%)
Net sales
21,581
23,700
23,019
+1,438
+6.7
(2.9)
Gross profit
11,697
12,460
11,883
+186
+1.6
(4.6)
8,798
9,280
9,041
+243
+2.8
(2.6)
2,899
3,180
2,841
(58)
(2.0)
(10.7)
2,912
2,886
(26)
(0.9)
(9.2)
% of net sales
13.5
3,180
Number of stores
265
274
274
+9
+3.4
+0.0
% of net sales
SG&A expenses
% of net sales
Operating profit
% of net sales
Segment profit
54.2
40.8
13.4
52.6
39.2
13.4
13.4
51.6
39.3
12.3
12.5
Figures in the table are rounded down
Segment profit is adjusted with the ordinary profit of quarterly consolidated statements of income
© AIN HOLDINGS INC. All Rights Reserved.
4
Consolidated B/S
Net cash became ¥(112,360) million due to the repayment of funds used to acquire shares of the Sakura
Pharmacy Group, etc.
End-FY2026
Assets
Current assets
Cash and deposits
Non-current
assets
Goodwill
Assets
Liabilities and Net Assets
173,173
50,925
336,474
194,182
Deferred
assets
Total assets
End-FY2027 1Q
(¥ million)
Current
liabilities
185,056
Non-current
liabilities
165,419
Short-term
borrowings
Long-term
borrowings
20,747
151,106
Current assets
Cash and deposits
Non-current
assets
Goodwill
159,171
Deferred
assets
Total liabilities
and net assets
509,647
Total assets
509,647
Net cash
(120,928)
Shareholders’ equity
ratio(%)
31.2
(¥ million)
Liabilities and Net Assets
Current
liabilities
189,530
Non-current
liabilities
161,127
157,991
Total liabilities
and net assets
508,649
173,026
54,265
335,623
191,376
508,649
Net cash
Shareholders’ equity
ratio(%)
Short-term
borrowings
Long-term
borrowings
20,584
146,040
(112,360)
31.0
Figures in the table are rounded down
Net cash = Cash and deposits – Interest-bearing debt
© AIN HOLDINGS INC. All Rights Reserved.
5
Assets
The balance of total assets decreased ¥998 million from the end of the fiscal year 2026, mainly reflecting
decrease in accounts receivable – trade and the amortization of goodwill.
(¥ million)
End-FY2026 1Q
Cash and deposits
Accounts receivable - trade
Inventories
Total current assets
Buildings and structures, net
Land
Total property, plant and
equipment
Goodwill
Total intangible assets
Investments securities
Deferred tax assets
Leasehold and guarantee
deposits
Total investments and other
assets
Total non-current assets
Total deferred assets
Total assets
End-FY2026
End-FY2027 1Q
Change
46,180
23,400
36,947
132,740
32,362
10,272
50,925
35,204
47,530
173,173
38,395
14,283
54,265
29,443
50,131
173,026
38,648
14,272
+3,340
(5,761)
+2,601
(147)
+253
(11)
51,907
61,541
61,698
+157
83,320
96,316
3,327
7,572
194,182
208,300
4,652
17,295
191,376
206,073
4,595
18,311
(2,806)
(2,227)
(57)
+1,016
31,299
33,571
33,790
+219
52,555
66,632
67,851
+1,219
200,779
333,520
336,474
509,647
335,623
508,649
(851)
(998)
Figures in the table are rounded down
Change:End-FY2027 1Q compared with End-FY2026
Capital expenditures (Property, plant and equipment and intangible assets +
Leasehold and guarantee deposits) totaled ¥4,208 million
© AIN HOLDINGS INC. All Rights Reserved.
6
Liabilities and Net Assets
Accounts payable – trade increased ¥4,498 million due to M&A activities and the opening of new stores. Shortterm and long-term borrowings decreased ¥5,229 million due to the repayment of funds used to acquire shares
of the Sakura Pharmacy Group, etc.
(¥ million)
End-FY2026 1Q
End-FY2026
End-FY2027 1Q
Change
Accounts payable – trade
84,222
113,874
118,372
+4,498
Short-term borrowings
31,912
20,747
20,584
(163)
Total current liabilities
154,690
185,056
189,530
+4,474
Long-term borrowings
25,479
151,106
146,040
(5,066)
36,437
165,419
161,127
(4,292)
Total liabilities
191,127
350,476
350,658
+182
Share capital
21,894
21,894
21,894
‐
Capital surplus
20,128
20,004
20,004
‐
100,796
116,130
114,572
(1,558)
Total shareholders’ equity
140,937
156,457
155,068
(1,389)
Total net assets
142,392
159,171
157,991
(1,180)
Total liabilities and net assets
333,520
509,647
508,649
(998)
Total non-current liabilities
Retained earnings
Figures in the table are rounded down
Change:End-FY2027 1Q compared with End-FY2026
© AIN HOLDINGS INC. All Rights Reserved.
7
Review
© AIN HOLDINGS INC. All Rights Reserved.
8
Consolidated (YoY results)
Net sales increased ¥44.2 billion, driven by the contribution of the newly acquired Sakura Pharmacy Group,
growth at existing stores, and the contribution of new stores opened in the previous fiscal year. On the other
hand, operating profit rose by only ¥0.4 billion due to the impact of drug price revisions and dispensing fee
revisions, weather-related factors, and the factor-based taxation, etc.
Net sales
Operating profit
¥132.9 billion → ¥177.1 billion +¥44.2 billion +33.2%
■ Dispensing
pharmacy
151.2
+¥42.7 billion
■ Retail
108.5
+¥1.5 billion
AT +¥1.2 billion
Ff +¥0.3 billion
21.5
2.9
FY2026
1Q
23.0
2.9
FY2027
1Q
AT:AINZ & TULPE Ff:Francfranc
¥4.2 billion → ¥4.6 billion +¥0.4 billion +8.4%
■ Dispensing
pharmacy
⇧ Three months' contribution
from Sakura Pharmacy Group
to increase in prescription
unit price
stores attributable to
increased customer count
and higher average
spending per customer,
along with contributions
from stores newly opened
in the previous period
⇧ Ff:Contribution from new
from Sakura Pharmacy Group
+¥1.1 billion
⇧ Growth in existing stores due
⇧ AT:Growth in existing
⇧ Three months' contribution
5.1
■ Retail
4.0
and dispensing fee revisions
⇧ AT:Growth in existing stores
attributable to increased
customer count and higher
average spending per
customer, along with
contributions from stores
newly opened in the previous
period
AT +¥0.1 billion ⇩ Ff:Weak sales of high-margin
Ff ¥(0.1) billion
products due to weather
2.8
2.8
(2.6)
(3.3) ■Administrative
factors
expense, etc.
stores opened in the prior
period
⇩ Impact of drug price revisions
⇩ Factor-based taxation
¥(0.7) billion
FY2026
1Q
Figures in the table are rounded down
FY2027
1Q
Decrease against profit:(
)
© AIN HOLDINGS INC. All Rights Reserved.
9
Consolidated (vs plan)
Net sales exceeded the plan by ¥2.5 billion due to steady growth in the number of prescriptions and the average
prescription price in the dispensing pharmacy business. On the other hand, operating profit fell short of the plan
by ¥0.9 billion, primarily because the retail business failed to meet its target for the number of customers due to
weather-related factors.
Net sales
Operating profit
¥174.6 billion → ¥177.1 billion +¥2.5 billion +1.4%
¥5.5 billion → ¥4.6 billion ¥(0.9) billion (17.5)%
■ Dispensing
pharmacy
147.8
+¥3.4 billion
151.2
■ Retail
■ Dispensing
pharmacy
¥(0.2) billion ⇩ Impact of drug price
⇧ Prescription volume and
unit price exceeded the
plan
5.3
5.1
revisions
■ Retail
¥(0.7) billion ⇩ AT and Ff: Failed to
AT ¥(0.2) billion
Ff ¥(0.5) billion
23.7
23.0
3.1
2.9
meet its target for the
number of customers
due to weather-related
factors
■Others
¥(0.2) billion ⇩ AYURA failed to meet
FY2027 FY2027
1Q plan 1Q results
AT:AINZ & TULPE Ff:Francfranc
their targets, etc.
to meet sales
¥(0.3) billion ⇩ Failure
targets
3.1
2.8
(2.9)
(3.3)
AT ¥(0.2) billion
Ff ¥(0.1) billion
■Administrative
expense, etc.
¥(0.4) billion ⇩ Factor-based taxation
FY2027 FY2027
1Q plan 1Q results
Figures in the table are rounded down
Decrease against profit:(
)
© AIN HOLDINGS INC. All Rights Reserved.
10
Number of Pharmacies and Stores
Opening
The number of new stores opened in the dispensing pharmacy business (including M&A) was 14, and the
number of new stores opened in the retail business was 6. As of the end of the first quarter of FY2027, the
dispensing pharmacy business had 2,143 stores and the retail business had 274 stores, bringing the total
number of stores to 2,417.
■ Results
■ Total stores End-FY2027 1Q results
FY2027 1Q
FY2027
Plan
Results
Dispensing pharmacy
14
14
Organic
M&A
Retail
AINZ & TULPE
Francfranc
11
3
6
6
0
10
4
6
6
0
20
20
Dispensing Pharmacy
9
8
Retail
1
1
Total
10
9
Closure
Total
Plan
80
40
40
24
15
9
104
2,417
Dispensing pharmacies 2,143
Retail stores
274
AINZ & TULPE 112
Francfranc
162
30
5
35
■ Transition of dispensing pharmacies
Organic
M&A
EV/EBITDA ratio
Closed
Sold
FY2024
19
21
4.41
13
5
FY2025
30
68
5.10
25
14
FY2026
41
861
6.40
30
25
FY2027 1Q
10
4
3.68
5
3
EV/EBITDA ratio=
EV(M&A: Purchase price)/EBITDA(Operating profit + Depreciation)
137
31
172
13
381
274 31
37
154
23
190
13
835
119
■:Dispensing pharmacies
■:Retail stores
The total number of stores includes Francfranc Hong Kong 7 stores
© AIN HOLDINGS INC. All Rights Reserved.
11
Average days of prescription and average prescription value
The number of prescriptions continues to show a slight downward trend due to the increase in the average days of
prescription. On the other hand, the average prescription value is rising due to the increase in the number of
prescription days and the growth in high-cost prescriptions. We will minimize the impact of the decline in the
number of prescriptions through patient acquisition initiatives and continue to expand our top line.
■ Average days of prescription
■ Average prescription price
(Day)
(%)
FY2024
40
FY2025
FY2026
130
FY2027
Existing store average prescription price index
(Indexed to 100 for the FY2023 1Q)
39
122
120
38.4
38
37.1
37
110
36.4
36
35.4
100
35
90
34
5
6
7
8
9
10
11
12
Excluding the Sakura Pharmacy Group
1
2
3
4 (Month)
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
FY2023
FY2024
FY2025
FY2026
FY2027
Average prescription price of existing stores for each fiscal year
Excluding the Sakura Pharmacy Group © AIN HOLDINGS INC. All Rights Reserved.
12
FY2027 Plan
© AIN HOLDINGS INC. All Rights Reserved.
13
FY2027 Plan (Dispensing Pharmacy Business)
The group forecasts net sales increase 11.7% YoY and operating profit increase 0.7% YoY, due to the impact of
dispensing fee revisions, and an increase in the average prescription price resulting from proper evaluation of
technical fees and a rise in high-cost prescriptions.
(¥ million)
FY2025
results
FY2026
results
FY2027
plan
YoY
change
YoY
change(%)
Net sales
384,783
556,424
621,500
+65,073
+11.7
Gross profit
40,485
63,372
67,120
+3,748
+5.9
17,708
27,925
31,470
+3,495
+12.5
22,776
35,397
35,650
+253
+0.7
24,286
35,760
35,430
(330)
(0.9)
% of net sales
SG&A expenses
% of net sales
Operating profit
% of net sales
Segment profit
% of net sales
10.5
4.6
5.9
6.3
11.4
5.0
6.4
6.4
10.8
5.1
5.7
5.7
Figures in the table are rounded down
Segment profit is adjusted with the ordinary profit of consolidated statements of income
© AIN HOLDINGS INC. All Rights Reserved.
14
FY2027 Plan (Retail Business)
The group forecasts net sales increase 9.7% YoY and operating profit increase 16.4% YoY due to new store
openings and growth in existing stores of AINZ & TULPE and Francfranc.
(¥ million)
FY2025
results
FY2026
results
FY2027
plan
YoY
change
YoY
change(%)
Net sales
61,041
80,255
88,000
+7,745
+9.7
Gross profit
30,030
41,235
45,220
+3,985
+9.7
25,248
34,791
37,720
+2,929
+8.4
4,782
6,443
7,500
+1,057
+16.4
4,804
6,528
7,500
+972
+14.9
% of net sales
SG&A expenses
% of net sales
Operating profit
% of net sales
Segment profit
% of net sales
49.2
41.4
7.8
7.9
51.4
43.4
8.0
8.1
51.4
42.9
8.5
8.5
Figures in the table are rounded down
Segment profit is adjusted with the ordinary profit of consolidated statements of income
© AIN HOLDINGS INC. All Rights Reserved.
15
FY4/27 Plan (Consolidated)
The group forecasts net sales increase 11.4% YoY and operating profit increase 8.9% YoY, due to the growth of
new stores in both businesses, the impact of dispensing fee revisions, and the full contribution of Sakura
Pharmacy Group.
(¥ million)
Net sales
Gross profit
% of net sales
SG&A expenses
% of net sales
Operating profit
% of net sales
Ordinary profit
% of net sales
Profit attributable to owners
of parent
% of net sales
Earnings per share(¥)
EBITDA
% of net sales
Annual dividend (¥)
Figures in the table are rounded down
FY2025
results
456,804
74,436
16.3
FY2026
results
647,834
108,878
16.8
FY2027
plan
YoY
change
721,500
117,000
+73,666
+8,122
16.2
YoY
change(%)
+11.4
+7.5
57,565
79,045
84,500
+5,455
+6.9
16,871
29,832
32,500
+2,668
+8.9
18,080
28,414
30,000
+1,586
+5.6
9,261
17,264
15,000
(2,264)
(13.1)
2.0
2.7
2.1
264.32
31,040
491.62
52,011
426.74
58,110
(64.88)
(13.2)
+6,099
+11.7
6.8
8.0
8.1
80.00
100.00
100.00
0.0
12.6
3.7
4.0
12.2
4.6
4.4
11.7
4.5
4.2
© AIN HOLDINGS INC. All Rights Reserved.
16
Appendix
© AIN HOLDINGS INC. All Rights Reserved.
17
Shareholder return
We have maintained shareholder returns based on progressive dividends, balancing growth investments and
shareholder returns. Going forward, while continuing to invest toward our medium-to-long-term vision, we will
target a dividend payout ratio of 30.0% as our medium-to-long-term approach to shareholder returns.
(¥)
180
Dividend per share
(%)
30.3
Medium-to-long-term targets
Dividends payout ratio 30.0%
30.0
23.4
Dividends payout ratio
20.3
20.0
60
10.0
0
Dividends
100 100
payout ratio
Dividend per share
120
0.0
FY
FY
FY
FY
FY
2008
2010
2015
2020
2025 2026 2027
Expec Plan
ted
Figures for FY2008 to FY2014 have been adjusted to reflect the stock split implemented in Oct. 2014
FY
FY
© AIN HOLDINGS INC. All Rights Reserved.
18
Digital transformation investments medium-term measures
In each business and whole the company, digital transformation measures to expand the scale of business, and
the upgrading of operations using IT, etc., are set as mid-term measures by fiscal 2027. The company provides
added value that only AIN Group can offer and improves operating efficiency.
Groupwide
Retail
Dispensing
pharmacy
Medium-term measures
Digital transformation promotion and service
enhancement in dispensing pharmacy operations
(Introducing digital medication history system
computers equipped with generative AI)
Realization of digital services at next generation
pharmacies
(Expand the function of app)
Digital transformation promotion and service
enhancement in store operations
(Introducing next generation point of sale and
self checkout system )
Promotion of digital marketing
(Realizing service appeals to app users)
FY2025
System selection
Effect verification
Integration of
patient
medication
notebooks
functions
Requirements
definition and
design
Payment
function
AINPay
FY2026
FY2027
Start of implementation
Introduced in 470 stores
Plan to introduce in
1,250 stores
App system
upgrade
Plan to start
personalized services
for patients
Developing next-generation POS and MD
systems
→ Introduce sequentially
Renewal of e-commerce and app
Start personalized services for patients
Automation of back-office operations
(Business sophistication and efficiency
improvement through the use of robotic process
automation and generative AI)
Add robotic process
automations as needed
Effect verification of
generative AI
Introduce generative AI
Establishment
of AIn Academy
System renewal
(Advancement of common platforms)
Accounting and education
management
System renewal
Enhance information security
Procurement and logistics management system,
Group database refresh
Plan to fully implement
AI agents
© AIN HOLDINGS INC. All Rights Reserved.
19
Human capital
We aim to hire about 500 new pharmacists, 300 new medical support staff, and 130 new retail staff and others
in fiscal 2027. The employee turnover rate among full-time employees has been declining as a result of efforts in
human resource strategy, including changes to the personnel system and human resource development initiatives.
■ No. of newly hired students
(people)
800
■ Full-time employee turnover rate
(%)
Pharmacists
Medical support staff
9
Retail staff and others
Full-time employee
Full-time employee
turnover rate
600
students
No. of newly hired
Full-time employee (pharmacists)
400
737
657
639
553
532
503
200
500
8
7.8
7.9
7.9
7
7.1
7.5
6.3
6
300
0
105
2024
135
2025
163
2026
130
2027 (year)
(plan)
5
0
FY2024
FY2025
FY2026
© AIN HOLDINGS INC. All Rights Reserved.
20
Sustainability management Materiality
In December 2025, we conducted a review of our materiality in light of the announcement of our medium-tolong-term vision and changes in the external environment. Going forward, by keeping in mind our diverse
stakeholders, including our customers, and by proactively adapting and taking action, we aim to achieve
sustainable corporate growth and create social, environmental, and economic value, thereby realizing
sustainability management.
-
Contribute to local healthcare
Combining trusted professional expertise with an ability to engage deeply with people,
support each individual’s aspirations for better health as primary care pharmacies
rooted in their communities and contribute to healthcare that treats and supports
people throughout the local community.
-
Provide lifestyles that enrich everyday life
As a Life & Style store brimming with little thrills that help customers discover even
more wonderful day, we enable them to create their own unique lifestyles.
-
Safety, peace of mind and trust
Deliver safety, peace of mind, and trust through our day-to-day operations
-
Protect the environment and reduce environmental impact
Contribute to environmental protection and reducing
environmental impact
-
Employee growth and engagement
Maximize the power of diverse talent, the source of business growth
-
Ensure sound management base
Reinforce sound management base
preamble Human rights for all people
- Cooperate with local communities and businesses
Promote the creation of a healthy society and the
implementation of sustainability activities together with local communities and
the supply chain
© AIN HOLDINGS INC. All Rights Reserved.
21
Inquiries related to this presentation should be addressed to
AIN HOLDINGS INC.
Corporate Planning Division
TEL: +81-3-5333-1812
https://www.ainj.co.jp/corporate/
This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell or
purchase any securities. Information contained herein may be changed or
revised without prior notice. This document may contain forecasting
statements as to future results of operations. No forecast statement can be
guaranteed and actual results of operations may differ from those projected.
© AIN HOLDINGS INC. All Rights Reserved.
22